MiR-210 e miR-152 e suas proteínas-alvo como biomarcadores por biópsia líquida em câncer de mama
Carregando...
Arquivos
Data
2019-02-25
Autores
Lopes, Beatriz Camargo
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
INTRODUÇÃO: A alta mortalidade do câncer de mama (CM) está relacionada com a ocorrência de metástase, processo que depende da angiogênese. A detecção de microRNAs circulantes por biópsia líquida, com destaque para o miR-210 e miR-152 no CM, é de grande importância para a determinação do diagnóstico precoce e prognóstico e, assim, podem contribuir para diminuir a mortalidade por CM. OBJETIVO: Identificar e validar microRNAs como biomarcadores circulantes não invasivos no diagnóstico e prognóstico de pacientes com CM e confirmar a atuação deles na angiogênese. MATERIAL E MÉTODOS: Amostras de fragmentos tumorais e de plasma foram coletados de 30 mulheres com CM, cinco com alterações benignas da mama e cinco de mulheres controles. A análise da expressão dos microRNAs foi realizada por RT-qPCR e a análise da expressão das proteínas-alvo por imunohistoquímica. Valores de p<0,05 foram considerados significantes. RESULTADOS: Como esperado, houve aumento da expressão do oncomiR-210 e diminuição do supressor miR152 nos fragmentos tumorais de CM. Já nas amostras de plasma de CM, foi verificado aumento de ambos os miRNAs. Por fim, constatou-se que as proteínas HIF-1α, IGF-1R e VEGF apresentaram aumento da expressão em CM, enquanto a proteína VHL apresentou diminuição. CONCLUSÃO: Em conclusão, foi observado aumento de expressão do miR-210 e diminuição do supressor tumoral miR-152 em fragmentos de CM validadas pela expressão de suas proteínas-alvo envolvidas na angiogênese. Ainda, o aumento da expressão de ambos miRNAs por biópsia líquida de mulheres com CM é promissor no diagnóstico e prognóstico dessa neoplasia, e os torna potenciais biomarcadores, além do benefício de serem detectados por uma ferramenta minimamente invasiva.
BACKGROUND: The high mortality of breast cancer (BC) is related to the occurrence of metastasis, a process that depends on angiogenesis. The detection of circulating microRNAs by liquid biopsy, as a highlight for miR210 and miR-152 in BC, is of great importance for the determination of early diagnosis and prognosis and, thus, may contribute to decrease BC mortality. OBJECTIVE: To identify and validate microRNAs as noninvasive circulating biomarkers in the diagnosis and prognosis of BC patients and to confirm their performance in angiogenesis. MATERIALS AND METHODS: Tumor fragments and plasma samples were collected from 30 women with BC, five with benign breast conditions and five of women controls. Expression of the microRNAs was performed by RT-qPCR and the analysis of target protein expression by immunohistochemistry. Values of p <0.05 were considered significant. RESULTS: As expected, there was an increase in oncomiR-210 expression and a decrease in miR-152 suppressor in BC tumor fragments. In the BC plasma samples, both miRNAs were increased. Finally, it was found that the HIF-1α, IGF-1R and VEGF proteins showed increased BC expression, whereas the VHL protein showed decrease. CONCLUSION: In conclusion, increase expression of miR-210 and decrease of miR-152 tumor suppressor in BC fragments was observed, validated by the expression of their target proteins involved in angiogenesis. Furthermore, the increased expression of both miRNAs by liquid biopsy of women with BC is promising in the diagnosis and prognosis of this neoplasm, making them potential biomarkers, in addition to the benefit of being detected by a minimally invasive tool.
BACKGROUND: The high mortality of breast cancer (BC) is related to the occurrence of metastasis, a process that depends on angiogenesis. The detection of circulating microRNAs by liquid biopsy, as a highlight for miR210 and miR-152 in BC, is of great importance for the determination of early diagnosis and prognosis and, thus, may contribute to decrease BC mortality. OBJECTIVE: To identify and validate microRNAs as noninvasive circulating biomarkers in the diagnosis and prognosis of BC patients and to confirm their performance in angiogenesis. MATERIALS AND METHODS: Tumor fragments and plasma samples were collected from 30 women with BC, five with benign breast conditions and five of women controls. Expression of the microRNAs was performed by RT-qPCR and the analysis of target protein expression by immunohistochemistry. Values of p <0.05 were considered significant. RESULTS: As expected, there was an increase in oncomiR-210 expression and a decrease in miR-152 suppressor in BC tumor fragments. In the BC plasma samples, both miRNAs were increased. Finally, it was found that the HIF-1α, IGF-1R and VEGF proteins showed increased BC expression, whereas the VHL protein showed decrease. CONCLUSION: In conclusion, increase expression of miR-210 and decrease of miR-152 tumor suppressor in BC fragments was observed, validated by the expression of their target proteins involved in angiogenesis. Furthermore, the increased expression of both miRNAs by liquid biopsy of women with BC is promising in the diagnosis and prognosis of this neoplasm, making them potential biomarkers, in addition to the benefit of being detected by a minimally invasive tool.
Descrição
Palavras-chave
Câncer de mama, MicroRNAs, Angiogênese, Biomarcadores, Breast cancer, Angiogenesis, Biomarkers